Proton-Gradient-Driven Porphyrin-Based Liposome Remote-Loaded with Imiquimod as In Situ Nanoadjuvants for Synergistically Augmented Tumor Photoimmunotherapy

• DOI: 10.1021/acsami.3c17133
• Publication Date: 2024-02-09T11:06:39Z
• Authors: Dechun Liu; Luyao Fu; Linlin Gong; Shasha Li; Kunwei Li; Kunhong Liu; Dan Yang
• Keywords: TLR7; Abscopal effect; Imiquimod; Tumor Antigen; Cancer Immunotherapy

Cancer immunotherapy is expected to achieve tumor treatment mainly by stimulating the patient's own immune system kill cells. However, low immunogenicity of and poor efficiency antigen presentation result in a variety solid tumors that do not respond immunotherapy. Herein, we designed proton-gradient-driven porphyrin-based liposome (PBL) with highly efficient Toll-like receptor 7 (TLR7) agonist (imiquimod, R837) encapsulation (R837@PBL). R837@PBL rapidly released R837 acid microenvironment activate TLR endosome inner membrane promote bone-marrow-derived dendritic cell maturation enhance presentation. upon laser irradiation triggered immunogenic death cells tumor-associated release after subcutaneous injection, activated TLR7, formed situ nanoadjuvants, enhanced efficiency. Photoimmunotherapy promoted infiltration cytotoxic T lymphocytes into tissues, inhibited growth treated abscopal tumors, exerted effective photoimmunotherapeutic effects. Hence, our nanoadjuvants are be an for providing novel approach synergistic photoimmunotherapy tumors.